Literature DB >> 8968538

Stereoselective recognition of the enantiomers of phenglutarimide and of six related compounds by four muscarinic receptor subtypes.

M Waelbroeck1, S Lazareno, O Pfaff, T Friebe, M Tastenoy, E Mutschler, G Lambrecht.   

Abstract

1. We have compared the binding properties of the enantiomers of phenglutarimide (1) and of six related compounds to M1 receptors in NB-OK-1 cells, M2 receptors in rat heart, M3 receptors in rat pancreas and the M4 receptors of rat striatum, with their functional (antimuscarinic) properties in rabbit vas deferens (M1/M4-like), guinea-pig atria (M2) and guinea-pig ileum (M3) receptors. The binding properties of the enantiomers of three of the compounds were also measured on cloned human m1-m4 receptors expressed by CHO cells, using [3H]-N-methylscopolamine ([3H]-NMS) as radioligand. 2. The high affinity enantiomers behaved as competitive antagonists in binding and pharmacological studies. (S)-phenglutarimide (pKi-M1 = 9.0/9.3) and (R)-thienglutarimide (pKi-M1 = 8.6/9.2) recognized selectively the native M1 > M4 > M3 > M2 receptors in tissues as well as the respective cloned receptors. 3. The pA2 values at the inhibitory heteroreceptors in the rabbit vas deferens, and at the guinea-pig atria and ileum for the seven more potent enantiomers were compatible with the previous classification of these receptors as M1/M4-like, M2 and M3, respectively. 4. Replacement of the phenyl by a thienyl ring or of the diethylamino by a piperidino group in the phenglutarimide molecule did not affect markedly the potencies of the high affinity enantiomer. In contrast, replacement of the phenyl by a cyclohexyl ring decreased 20 fold the active enantiomers potency. Methylation of the piperidine-2,6-dione nitrogen also reduced markedly the eutomers' affinities, more on the M1 than on the other subtypes. 5. The selectivity profiles (recognition of four receptor subtypes) of six of the seven less active enantiomers were different from the corresponding more active enantiomers selectivity profiles, suggesting that the preparations used in this study were pure. However, we cannot not exclude the hypothesis that the batch of (S)-thienglutarimide used in this study was contaminated by less than 0.02% of the eutomer. 6. In contrast with the eutomer binding site, replacement of the phenyl ring by a thienyl or cyclohexyl ring did not affect binding of the low affinity enantiomers to the muscarinic receptor or the [3H]-NMS-receptor complex. The replacement of the diethylamino group by a piperidine ring, and N-methylation of the piperidine-2,6 dione moiety increased slightly these enantiomers' potencies. 7. The muscarinic receptors were extremely stereoselective, and had up to 20000 fold lower affinity for the less active enantiomers. However, the stereochemical requirements of the muscarinic receptor subtypes were different for the enantiomers of compounds 1-7, being most stringent at M1 receptors. 8. The weaker enantiomers behaved as competitive antagonists in pharmacological studies, at least in the concentration-range investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968538      PMCID: PMC1915812          DOI: 10.1111/j.1476-5381.1996.tb16041.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Optical isomerism and pharmacological action, a generalization.

Authors:  C C PFEIFFER
Journal:  Science       Date:  1956-07-06       Impact factor: 47.728

2.  80% of muscarinic receptors expressed by the NB-OK 1 human neuroblastoma cell line show high affinity for pirenzepine and are comparable to rat hippocampus M1 receptors.

Authors:  M Waelbroeck; J Camus; M Tastenoy; J Christophe
Journal:  FEBS Lett       Date:  1988-01-04       Impact factor: 4.124

Review 3.  Muscarinic receptor differentiation.

Authors:  F Mitchelson
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

Review 4.  pA2 and receptor differentiation: a statistical analysis of competitive antagonism.

Authors:  R J Tallarida; A Cowan; M W Adler
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

5.  The relative potencies of some agonists at M2 muscarinic receptors in guinea-pig ileum, atria and bronchi.

Authors:  R B Barlow; P Weston-Smith
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

6.  Stereochemical analogs of a muscarinic, ganglionic stimulant. 2. Cis and trans olefinic, epoxide, and cyclopropane analogs related to 4-[N-(3-chlorophenyl)carbamoyloxy]-2-butynyltrimethylammonium chloride (McN-A-343).

Authors:  W L Nelson; D S Freeman; F F Vincenzi
Journal:  J Med Chem       Date:  1976-01       Impact factor: 7.446

7.  Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes.

Authors:  G Lambrecht; R Feifel; U Moser; A J Aasen; M Waelbroeck; J Christophe; E Mutschler
Journal:  Eur J Pharmacol       Date:  1988-10-11       Impact factor: 4.432

8.  Differential stereoselectivity of methotrimeprazine enantiomers for selected central nervous system receptor types.

Authors:  T A Robert; A N Hagardorn; E A Daigneault
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

9.  The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips.

Authors:  W D Paton; M A Zar
Journal:  J Physiol       Date:  1968-01       Impact factor: 5.182

10.  Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes.

Authors:  M Eltze; V Figala
Journal:  Eur J Pharmacol       Date:  1988-12-06       Impact factor: 4.432

View more
  5 in total

1.  Receptor binding studies of soft anticholinergic agents.

Authors:  F Huang; P Buchwald; C E Browne; H H Farag; W M Wu; F Ji; G Hochhaus; N Bodor
Journal:  AAPS PharmSci       Date:  2001

2.  Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics.

Authors:  Fenglei Huang; Clinton E Browne; Whei-Mei Wu; Attila Juhász; Fubao Ji; Nicholas Bodor
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

3.  Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics.

Authors:  Whei-Mei Wu; Peter Buchwald; Nobuhiro Mori; Fubao Ji; JiaXiang Wu; Nicholas Bodor
Journal:  Pharm Res       Date:  2005-09-26       Impact factor: 4.200

4.  Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines.

Authors:  R Budriesi; S Cacciaguerra; R D Toro; M L Bolognesi; A Chiarini; A Minarini; M Rosini; S Spampinato; V Tumiatti; C Melchiorre
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

5.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.